Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel(Wayne State University), Leena Gandhi(Harvard University), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Alberto Chiappori(Moffitt Cancer Center), Howard West(Swedish Medical Center), Michele C. Azada(University of California, Irvine), Peter N. Morcos(La Roche College), Ruey-min Lee(La Roche College), Linta Garcia(Chugai Pharma (United States)), Li Yu(La Roche College), Frédéric Boisserie(La Roche College), Laura Di Laurenzio(La Roche College), Sophie Golding(La Roche College), Jotaro Sato, Shumpei Yokoyama, Tomohiro Tanaka, Sai‐Hong Ignatius Ou(University of California, Irvine)
Cited by 693